C-erbB_2、p16基因在卵巢肿瘤中的表达及其临床意义的研究

Study on expressions and clinical significance of C erbB 2 and P16 genes in ovarian neoplasms

目的：探讨卵巢肿瘤中癌基因Ｃ－ｅｒｂＢ２及抑癌基因ｐ１６的表达及其与临床病理特征及患者预后的关系。方法：用免疫组化ＡＢＣ法，分析４９份卵巢恶性肿瘤、１２份交界性肿瘤、１５份良性肿瘤石蜡包埋组织中Ｃ－ｅｒｂＢ２、ｐ１６的表达情况。结果：①在卵巢恶性肿瘤、交界性肿瘤、良性肿瘤之间Ｃ－ｅｒｂＢ２的表达差异有显著性（Ｐ＜０．０１）。Ｃ－ｅｒｂＢ２的表达率及表达强度与组织分化程度患者及生存期有显著相关性（Ｐ＜０．０５），Ｃ－ｅｒｂＢ２的过度表达见于恶性程度高、组织分化差、患者预后不良的肿瘤中。②在卵巢恶性肿瘤、交界性肿瘤、良性肿瘤之间ｐ１６的表达差异有显著性（Ｐ＜０．０１）。其表达强度与组织分化程度及临床分期有显著相关性，在恶性程度较高、组织分化差、较晚期的肿瘤中ｐ１６的表达较弱。结论：癌基因Ｃ－ｅｒｂＢ２及抑癌基因ｐ１６在卵巢癌组织中广泛存在，并与其临床病理指标之间有一定的相关性，提示这些基因在卵巢癌的发生、发展中起一定作用，并对患者预后的判断及治疗有一定的指导意义。对各基因之间复杂的相互作用、协同作用有待进一步研究。

Objectives:To study on the expression patterns of oncogene C erbB 2 and suppressor gene P16 in ovarian neoplasms,to compare these patterms with clinicopathological features and to assess their prognostic value.Methods:Using ABC immunohistochemical method,the authors investigated the expressions of C erbB 2 and P16 genes in paraffin embeded 49 sampla of malignant ovarian neoplasms,12 samples of borderline ovarian neoplasms and 15 sampla of benign ovarian neoplasms.Results:①The expression of C erbB 2 among the malignant,borderline and benign ovarian neoplasms was significant difference( P <0.01).The expressive rate and espressive intensity of C erbB 2 were associated with differentiation of neoplasm tissues and survival stage of patients( P >0.05).The high expression of C erbB 2 was found in those neoplasms which were more malignant and poorer differentiated and shorter survival stage of patients.②The expressions among the maligant,borderline and benign ovarian neoplasms were significant difference( P <0.01).The expressive rate and expressive intensity of P16 were associatecl with differentiation of neoplasms tissue and clinical stage.The expression of P16 was lower in poorer differentiated and later stage neoplasms.Conclusions:Oncogene C erbB 2 and suppressor gene P16 widely exist in tissues of ovarian neoplasms and is associated with clinicopathological features.They may play an important role in the development and progression of ovarian neoplasms.